Trials

Clinical research is for everyone

Inclusion is a major value for the EMN, particularly when it comes to clinical trials. The myeloma community is in fact highly heterogeneous and the EMN strongly believes that the same high-quality treatments should be offered to any patients, regardless of their gender, race, ethnicity, sexual orientation, disability, religion, age, cultural backgrounds, life experiences, thoughts, and ideas. We are extremely grateful for the fundamental role our patients play in the EMN clinical studies, and the contribution of each one of them is equally recognized and appreciated.

 
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation – The Majestec-4 study
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
COVID-19 INFECTION IN MULTIPLE MYELOMA PATIENTS: AN EUROPEAN PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL STUDY
A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis
PHASE II STUDY OF IBERDOMIDE (CC220) MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia trial)
CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE III TRIAL.
A retrospective observational multicenter study on the management and outcome of patients with systemic AL amyloidosis in Europe
Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis The Alcaeus Study
Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for Treatment of Myeloma Patients Presenting with Extramedullary Disease. The Antares Study
A multicenter, open label, randomized phase ii study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (dara-vcd) versus the association of bortezomib-thalidomide-dexamethasone (vtd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (mm) young patients eligible for autologous stem cell transplantation
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-Dose Therapy. The Perseus Study
Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase 2 Study
A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor: The APOLLO Study
Ixazomib in combination with Thalidomide-Dexamethasone in patients with relapsed and/or refractory multiple myeloma
Carfilzomib and lenalidomide-based treatment for transplant eligible and non-transplant eligible newly diagnosed primary plasma cell leukemia patients
A multicenter, open label, randomized phase ii study of mln9708 plus oral dexamethasone or plus oral cyclophosphamide and dexamethasone or plus bendamustine and dexamethasone or plus oral cyclophosphamide, thalidomide and dexamethasone followed by maintenance with mln9708 or placebo treatment in newly diagnosed elderly multiple myeloma patients
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in first relapse after prior 1st line treatment with Lenalidomide and Bortezomib.